← Leaderboards
Stephan Menne
University Of Kansas Medical Center
$2,795,660
Attributed
$6,553,419
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,553,419 · 4
By mechanism
R01$6,102,744 · 3
R21$450,675 · 1
Top collaborators
- Yanming Du6 shared
- Ju-Tao Guo6 shared
- Severin O Gudima5 shared
- Jianming Hu4 shared
Most similar at University Of Kansas Medical Center
Same institution · by research overlap
- Severin O Gudima$5,431,875
Others in their field
Top investigators on “Hepatocyte”
- David Heimbrook · Leidos Biomedical Research, Inc.$31,285,017
- Mark A Kay · Stanford University$31,244,013
- Charles M. Rice · Rockefeller University$27,314,965
- Stephen Lev Hoffman · Sanaria, Inc.$26,407,941
- Stefan H.i. Kappe · Seattle Children'S Hospital$25,211,763
- Michael H Nathanson · Yale University$22,903,080
Research focus
HepatocyteChronic Hepatitis BWoodchuckWoodchuck Hepatitis B VirusHepatitis B VirusPharmaceutical PreparationsViralMutantIn VitroVirionIn VivoInfectionAntiviral AgentsKineticsAffectLiverPrimary Carcinoma Of The Liver CellsInhibitor/AntagonistImmune ResponseReportingHepadnaviridaePredispositionAnimal ModelChronic
Grant awards (15)
Developing Woodchucks Susceptible to Hepatitis B Virus Infection by Modifying the Virus or Host$800,416
R01 · FY2025 · AI · contact PI
Exploring Hepatitis B Virus PreCore Gene Functions in Woodchucks$196,425
R21 · FY2025 · AI · contact PI
Developing Woodchucks Susceptible to Hepatitis B Virus Infection by Modifying the Virus or Host$820,940
R01 · FY2024 · AI · contact PI
Exploring Hepatitis B Virus PreCore Gene Functions in Woodchucks$254,250
R21 · FY2024 · AI · contact PI
Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors$537,218
R01 · FY2018 · AI
Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors$511,927
R01 · FY2017 · AI
Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors$578,621
R01 · FY2016 · AI
Super-infection and virus spread during chronic hepadnaviral infection$319,945
R01 · FY2016 · CA
Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors$669,728
R01 · FY2015 · AI
Super-infection and virus spread during chronic hepadnaviral infection$319,945
R01 · FY2015 · CA
Evaulation of therapeutic benefits of HBV nucleocapsid assembly inhibitors$405,835
R01 · FY2014 · AI
Super-infection and virus spread during chronic hepadnaviral infection$310,347
R01 · FY2014 · CA
Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors$182,968
R01 · FY2014 · AI
Super-infection and virus spread during chronic hepadnaviral infection$305,320
R01 · FY2013 · CA
Super-infection and virus spread during chronic hepadnaviral infection$339,534
R01 · FY2012 · CA